EGFR and non-small cell lung carcinoma: Early-stage EGFR-mutated non-small-cell lung cancer (NSCLC) cases usually have a better prognosis than wild-type or KRAS-mutated cases, even without tyrosine-kinase inhibitor (TKI) application15–17.